Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
SAN DIEGO and TORONTO, March 03, 2016 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the following upcoming conferences:
- Cowen & Company 36th Annual Healthcare Conference
Aptose’s corporate presentation is scheduled to take place at 2:00 p.m. ET on Monday, March 7, 2016 in Boston, MA. A corresponding live webcast of the presentation can be accessed by visiting:
- 28th Annual ROTH Conference
Aptose’s corporate presentation is scheduled to take place at 10:30 a.m. ET on Monday, March 14, 2016 in Dana Point, CA. A corresponding live webcast of the presentation can be accessed by visiting:
The audio webcasts will be archived shortly after the live event and will be available for 90 days through the Aptose website at www.aptose.com.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide additive or synergistic efficacy with existing anti-cancer therapies and regimens without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Greg Chow, CFO 647-479-9828 [email protected] BCC Partners Karen L. Bergman or Susan Pietropaolo 650-575-1509 or 845-638-6290 [email protected] or [email protected]
